China Pharma Holdings Inc. Announces 1-for-10 Reverse Stock Split

China Pharma Holdings Inc. is implementing a 1-for-10 reverse stock split, effective April 15. The company's stock will continue trading on the NYSE American under the symbol "CPHI" with a new CUSIP number. Every 10 shares of common stock will be converted into one share, and fractional shares will be rounded up to the next whole number. The reverse split was authorized by the Board on October 22, 2024, and adopted by shareholders through the Annual Meeting on December 22, 2024. The Board fixed a ratio of 1:10 on March 26, 2025.

China Pharma Holdings Inc. (CPHI) has announced plans to implement a 1-for-10 reverse stock split on its common stock, effective Tuesday, April 15, 2025. The company's stock will continue to trade on the NYSE American under the symbol "CPHI" but will be assigned a new CUSIP number (16941T 401) following the split.

The reverse stock split, which was authorized by the company's Board of Directors on October 22, 2024, and adopted by shareholders through the Annual Meeting on December 22, 2024, will convert every 10 shares of common stock into one share. Any fractional shares resulting from the split will be rounded up to the nearest whole share.

The Board of Directors fixed the ratio at 1:10 on March 26, 2025. This move is expected to simplify the trading of the company's stock and potentially improve liquidity. The reverse stock split will not alter the percentage interest of any stockholder, except for adjustments resulting from the treatment of fractional shares.

China Pharma Holdings Inc. is a specialty pharmaceutical company focused on developing, manufacturing, and marketing products for high-incidence and high-mortality conditions in China. The company's cost-effective business model is supported by market demand and new GMP-certified product lines. It also boasts a broad and expanding nationwide distribution network across major cities and provinces in China.

Investors should be aware of the potential impact of the reverse stock split on their holdings. While the number of shares they own will decrease, the value of each share will increase proportionally. It is recommended that investors review the details of the reverse stock split and consult with their financial advisors if they have any questions or concerns.

This announcement comes as part of China Pharma Holdings Inc.'s ongoing efforts to improve its financial health and position itself for future growth. The company's forward-looking statements, as outlined in its press release, include risks and uncertainties such as the achievability of financial guidance, success of new product development, and changes in product demand. Investors should review these statements carefully and stay informed about the company's progress and developments.